Nvidia announces partnership with Britain's GSK for drug, vaccine discovery
U.S. computer giant Nvidia Corporation on Monday announced a partnership with global healthcare company GSK and its AI group, which is applying computation to drug and vaccine discovery process.
According to Nvidia, GSK has recently established a new London-based AI hub, which will leverage GSK's genetic and genomic data to improve the process of designing and developing transformational medicines and vaccines.
GSK's hub will utilize biomedical data, AI methods and advanced computing platforms to unlock genetic and clinical data.
The GSK AI hub, once fully operational, will be home to its Britain-based AI team, including GSK AI Fellows, a new professional training program and now scientists from Nvidia, the company said.
GSK will have access to Nvidia's Cambridge-1, Britain's most powerful AI supercomputer, also announced Monday by Nvidia.
"Because of the massive size of the datasets we use for drug discovery, we need to push the boundaries of hardware and develop new machine learning software," said Kim Branson, senior vice president at GSK.
"GSK and Nvidia together will help push the boundaries of what AI can do and put vast data sources to work to advance the discovery of new medicines and vaccines," said Kimberly Powell, vice president of healthcare at Nvidia.